Free Newsletter
Combo therapy revs up stem cells to repair damage
A research team at Imperial College in London has engineered a new method that spurs bone marrow to make and release two new types of stem cells that the body can use to repair damaged bone, blood vessels and cartilage. And the team plans to launch new animal trials to further advance their work.
The treatment relies on a combination of Genzyme's Mozobil and a human growth factor, which scientists say can create a rich new stream of stem cells. Lead scientist Sara Rankin says that today the body essentially sends a single fire engine to deal with every fire-- or health crisis--that breaks out in the body. This new method has the potential to dispatch a hundred fire engines to the scene of a crisis.
"This has huge and broad implications. It's an untapped process," Rankin told the Guardian. "Suppose a person comes in to hospital having had a heart attack. You give them these drugs and stem cells are quickly released into the blood. We know they will naturally home in on areas of damage, so if you've got a broken bone, or you've had a heart attack, the stem cells will go there. In response to a heart attack, you'd accelerate the repair process."
- read the report in the Guardian
- check out the story in New Scientist
Related Articles:
FDA blesses Genzyme's Mozobil
Genzyme, Abbott score FDA approvals
Tissue regeneration a success with new heart
Breast cancer stem cells found in bone marrow (Oct 2006)
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: